Safety and Virologic Impact of Immune Checkpoint Inhibitors in Solid Tumor Patients with Chronic Hepatitis C Virus Infection

Yibirin, Marcel; Mustafayev, Khalis; Hosry, Jeff; Pundhir, Pooja; Klingen, Joseph T.; Guevara, Eduardo Yepez; Granwehr, Bruno; Kaseb, Ahmed; Naing, Aung; Patel, Sapna; Shah, Amishi Yogesh; Skoulidis, Ferdinandos; Tawbi, Hussein A.; Wang, Lan; Miller, Ethan; Zhang, Hao Chi; Torres, Harrys A.

doi:10.2139/ssrn.4053480

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are further substantiated by other multicenter studies, confirming the safety of ICI treatment in patients with HCC without the risk of HCV reactivation [ 101 , 102 ]. Overall, the history of HCC infection is not a contraindication to ICI therapy in these HCC patients, and there is a low concern for reactivation in this population [ 103 , 104 ].…”

Section: Potential For Hepatitis B and C Reactivationmentioning

confidence: 99%

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma and Their Hepatic-Related Side Effects: A Review

Ruli,

Pollack,

Lodh

et al. 2024

Cancers

View full text Add to dashboard Cite

Primary liver cancer is one of the leading causes of cancer mortality worldwide, with hepatocellular carcinoma (HCC) being the most prevalent type of liver cancer. The prognosis of patients with advanced, unresectable HCC has historically been poor. However, with the emergence of immunotherapy, specifically immune checkpoint inhibitors (ICIs), there is reason for optimism. Nevertheless, ICIs do not come without risk, especially when administered in patients with HCC, given their potential underlying poor hepatic reserve. Given their novelty in the management of HCC, there are few studies to date specifically investigating ICI-related side effects on the liver in patients with underlying HCC. This review will serve as a guide for clinicians on ICIs’ role in the management of HCC and their potential side effect profile. There will be a discussion on ICI-related hepatotoxicity, the potential for hepatitis B and C reactivation with ICI use, the potential for the development of autoimmune hepatitis with ICI use, and the risk of gastrointestinal bleeding with ICI use. As ICIs become more commonplace as a treatment option in patients with advanced HCC, it is imperative that clinicians not only understand the mechanism of action of such agents but also understand and are able to identify hepatic-related side effects.

show abstract

Section: Potential For Hepatitis B and C Reactivationmentioning

confidence: 99%

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma and Their Hepatic-Related Side Effects: A Review

Ruli,

Pollack,

Lodh

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…In this issue of The American Journal of Gastroenterology , Yibirin et al (5) demonstrate that those with active HCV infection overall have a good prognosis with concomitant ICI therapy and should not only be considered for this type of cancer therapy but also should not be left out from clinical trials using these therapies.…”

mentioning

confidence: 99%

Immune-Checkpoint Inhibitors in the Hepatitis C–Infected Patient: To Use or Not to Use?

Barnhill

Vargas

2023

Am J Gastroenterol

View full text Add to dashboard Cite

Safety and Virologic Impact of Immune Checkpoint Inhibitors in Solid Tumor Patients with Chronic Hepatitis C Virus Infection

Cited by 2 publications

References 0 publications

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma and Their Hepatic-Related Side Effects: A Review

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma and Their Hepatic-Related Side Effects: A Review

Immune-Checkpoint Inhibitors in the Hepatitis C–Infected Patient: To Use or Not to Use?

Contact Info

Product

Resources

About